Incyte Corporation (INCY) Quick Ratio (Acid-Test): 3.25
Is Incyte Corporation’s quick ratio (acid-test) high or low?
Incyte Corporation's quick ratio (acid-test) of 3.25 is in line with its 5-year average of 3.29, near the high end of its 5-year range (1.94–3.71).
As of Sunday, June 21, 2026. 25.24% above its 12-month average of 2.59.
INCY Quick Ratio (Acid-Test) Chart
INCY Average Quick Ratio (Acid-Test) Chart
INCY Current vs Average Quick Ratio (Acid-Test) Chart
INCY Quick Ratio (Acid-Test) Metrics
QUICK RATIO (ACID-TEST)
3.25
QUICK RATIO (ACID-TEST) AVG TTM
2.59
QUICK RATIO (ACID-TEST) AVG 3Y
3.09
QUICK RATIO (ACID-TEST) AVG 5Y
3.29
QUICK RATIO (ACID-TEST) AVG 10Y
3.77
QUICK RATIO (ACID-TEST) AVG 15Y
3.76
QUICK RATIO (ACID-TEST) AVG 20Y
3.89
CURRENT VS TTM AVG
+25.24%
CURRENT VS 3Y AVG
+5.01%
CURRENT VS 5Y AVG
-1.07%
CURRENT VS 10Y AVG
-13.69%
CURRENT VS 15Y AVG
-13.49%
CURRENT VS 20Y AVG
-16.50%
INCY Competitors' Quick Ratio (Acid-Test)
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Incyte Corporation (INCY) | $19.62B | 3.25 | 2.59 | 3.09 | 3.29 |
| Labcorp Holdings Inc. (LH)vs › | $20.98B | 1.23 | 1.27 | 1.23 | 1.37 |
| Viatris Inc. (VTRS)vs › | $17.90B | 0.74 | 0.86 | 1.00 | 0.90 |
| Zimmer Biomet Holdings, Inc. (ZBH)vs › | $17.02B | 1.10 | 1.04 | 0.96 | 0.94 |
| Hologic, Inc. (HOLX)vs › | $16.97B | 3.06 | 3.04 | 3.12 | 2.66 |
| United Therapeutics Corporation (UTHR)vs › | $22.78B | 6.28 | 5.66 | 6.29 | 6.48 |
| BioNTech SE (BNTX)vs › | $22.98B | 7.49 | 7.42 | 7.84 | 6.36 |
| Mettler-Toledo International Inc. (MTD)vs › | $23.13B | 0.81 | 0.77 | 0.77 | 0.79 |
| Waters Corporation (WAT)vs › | $23.17B | 1.27 | 1.39 | 1.50 | 1.54 |
| Veeva Systems Inc. (VEEV)vs › | $24.90B | 4.89 | 4.70 | 4.39 | 4.08 |
Liquidity Comparison
Quick Ratio
3.25
Excludes inventory
Current Ratio
3.32
Includes inventory
Incyte Corporation Quick Ratio (Acid-Test) Formula & Definition
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Incyte Corporation Quick Ratio (Acid-Test) FAQ
- What is the quick ratio (acid-test) for Incyte Corporation (INCY)?
- The quick ratio (acid-test) for INCY stock is 3.25.
- Is Incyte Corporation's quick ratio (acid-test) high or low?
- Incyte Corporation's quick ratio (acid-test) of 3.25 is in line with its 5-year average of 3.29, near the high end of its 5-year range (1.94–3.71).
- What is the TTM average quick ratio (acid-test) for Incyte Corporation (INCY)?
- The TTM average quick ratio (acid-test) for INCY stock is 2.59.
- What is the 3Y average quick ratio (acid-test) for Incyte Corporation (INCY)?
- The 3Y average quick ratio (acid-test) for INCY stock is 3.09.
- What is the 5Y average quick ratio (acid-test) for Incyte Corporation (INCY)?
- The 5Y average quick ratio (acid-test) for INCY stock is 3.29.
- What is the 10Y average quick ratio (acid-test) for Incyte Corporation (INCY)?
- The 10Y average quick ratio (acid-test) for INCY stock is 3.77.
- What is the 15Y average quick ratio (acid-test) for Incyte Corporation (INCY)?
- The 15Y average quick ratio (acid-test) for INCY stock is 3.76.
- What is the 20Y average quick ratio (acid-test) for Incyte Corporation (INCY)?
- The 20Y average quick ratio (acid-test) for INCY stock is 3.89.
Incyte Corporation Quick Ratio (Acid-Test) History
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2025-12-31 | 3.25 |
| 2024-12-31 | 1.94 |
| 2023-12-31 | 3.69 |
| 2022-12-31 | 3.50 |
| 2021-12-31 | 3.62 |
| 2020-12-31 | 3.71 |
| 2019-12-31 | 4.81 |
| 2018-12-31 | 4.29 |
| 2017-12-31 | 3.99 |
| 2016-12-31 | 3.62 |
| 2015-12-31 | 5.00 |
| 2014-12-31 | 3.16 |
| 2013-12-31 | 5.14 |
| 2012-12-31 | 2.27 |
| 2011-12-31 | 2.29 |
| 2010-12-31 | 4.01 |
| 2009-12-31 | 4.94 |
| 2008-12-31 | 4.08 |
| 2007-12-31 | 7.23 |
| 2006-12-31 | 6.64 |
| 2005-12-31 | 12.71 |
| 2004-12-31 | 15.29 |
| 2003-12-31 | 7.40 |
| 2002-12-31 | 5.90 |
| 2001-12-31 | 6.87 |
| 2000-12-31 | 8.49 |
| 1999-12-31 | 2.13 |
| 1998-12-31 | 2.63 |
| 1997-12-31 | 2.74 |
| 1996-12-31 | 2.05 |
Related Metrics
About Incyte Corporation
Incyte Corporation is a biopharmaceutical firm engaged in the research, development, and global marketing of its own innovative therapies. Its current product offerings include JAKAFI, prescribed for myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that targets oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor utilized for chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. Beyond its marketed drugs, Incyte's pipeline features several promising candidates. Among its clinical-stage assets are ruxolitinib, targeting steroid-refractory chronic graft-versus-host disease (GVHD), and itacitinib, which is undergoing Phase II/III trials for newly diagnosed chronic GVHD. Pemigatinib is also being investigated for conditions such as bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and other tumor types. Further advancing its research, the company is developing Parsaclisib, currently in Phase II studies for follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma. Additionally, Retifanlimab is in Phase II development for multiple indications, including MSI-high endometrial cancer, Merkel cell carcinoma, anal cancer, and non-small cell lung cancer. Incyte maintains a broad network of strategic alliances with numerous pharmaceutical and biotech companies, including key partners like Novartis International Pharmaceutical Ltd., Eli Lilly and Company, and Agenus Inc., among many others. These collaborations extend to clinical trials, notably joint efforts with MorphoSys AG and Xencor, Inc., to evaluate a combination therapy involving tafasitamab, plamotamab, and lenalidomide for patients with recurrent or resistant diffuse large B-cell lymphoma and follicular lymphoma. Established in 1991, the corporation's main offices are situated in Wilmington, Delaware.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- William J. Meury